NCT04840849View on ClinicalTrials.gov

Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

November 18, 2021

Study Completion Date

November 18, 2021

Conditions

Evaluate PK Profile

Interventions

BIOLOGICAL

nirsevimab

Drug: injection, a single fixed IM dose on day 1 only.

OTHER

Placebo

Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.

Trial Locations (1)

200040

Research Site, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

IQVIA RDS (Shanghai) Co., Ltd.

INDUSTRY

lead

AstraZeneca

INDUSTRY